Operating Income (Loss) in USD of Propanc Biopharma, Inc. from Q4 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Propanc Biopharma, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q4 2010 to Q3 2025.
  • Propanc Biopharma, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$4.67M, a 1507% decline year-over-year.
  • Propanc Biopharma, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$61.7M, a 4274% decline year-over-year.
  • Propanc Biopharma, Inc. annual Operating Income (Loss) for 2025 was -$57.3M, a 3629% decline from 2024.
  • Propanc Biopharma, Inc. annual Operating Income (Loss) for 2024 was -$1.54M, a 13.5% increase from 2023.
  • Propanc Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$1.78M, a 10.8% increase from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Propanc Biopharma, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$61.7M -$4.67M -$4.38M -1507% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$57.3M -$3.65M -$3.39M -1303% 01 Apr 2025 30 Jun 2025 10-K 29 Sep 2025
Q1 2025 -$53.9M -$53.1M -$52.7M -12524% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$1.18M -$213K +$225K +51.3% 01 Oct 2024 31 Dec 2024 10-Q 14 Feb 2025
Q3 2024 -$1.41M -$291K +$126K +30.3% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$1.54M -$260K -$50.3K -24% 01 Apr 2024 30 Jun 2024 10-K 29 Sep 2025
Q1 2024 -$1.49M -$421K -$34.7K -8.97% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$1.45M -$438K +$170K +28% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025
Q3 2023 -$1.62M -$417K +$156K +27.2% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$1.78M -$210K +$390K +65% 01 Apr 2023 30 Jun 2023 10-K 30 Sep 2024
Q1 2023 -$2.17M -$386K +$116K +23.1% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 -$2.28M -$608K -$205K -50.7% 01 Oct 2022 31 Dec 2022 10-Q 20 Feb 2024
Q3 2022 -$2.08M -$573K -$86.8K -17.9% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$1.99M -$599K +$128K +17.6% 01 Apr 2022 30 Jun 2022 10-K 28 Sep 2023
Q1 2022 -$2.12M -$502K -$74.2K -17.3% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$2.04M -$403K -$129K -47.2% 01 Oct 2021 31 Dec 2021 10-Q 10 Feb 2023
Q3 2021 -$1.92M -$486K -$103K -26.8% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$1.81M -$727K -$133K -22.4% 01 Apr 2021 30 Jun 2021 10-K 28 Sep 2022
Q1 2021 -$1.68M -$428K +$179K +29.5% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$1.86M -$274K +$1.11M +80.2% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 -$2.97M -$383K +$526K +57.9% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$3.49M -$594K +$242K +29% 01 Apr 2020 30 Jun 2020 10-K 28 Sep 2021
Q1 2020 -$3.74M -$607K -$35.4K -6.2% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 -$3.7M -$1.38M -$626K -82.6% 01 Oct 2019 31 Dec 2019 10-Q 12 Feb 2021
Q3 2019 -$3.08M -$909K -$461K -103% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 -$2.61M -$836K -$325K -63.4% 01 Apr 2019 30 Jun 2019 10-K 01 Oct 2020
Q1 2019 -$2.29M -$572K +$235K +29.2% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$2.53M -$758K +$679K +47.3% 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020
Q3 2018 -$3.2M -$449K +$755K +62.7% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 -$3.96M -$512K +$598K +53.9% 01 Apr 2018 30 Jun 2018 10-K 15 Oct 2019
Q1 2018 -$4.56M -$807K +$740K +47.8% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$5.3M -$1.44M +$472K +24.7% 01 Oct 2017 31 Dec 2017 10-Q 14 Feb 2019
Q3 2017 -$5.77M -$1.2M -$29.7K -2.53% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$5.74M -$1.11M +$2.35M +67.9% 01 Apr 2017 30 Jun 2017 10-K 17 Sep 2018
Q1 2017 -$8.09M -$1.55M -$257K -19.9% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$7.83M -$1.91M -$765K -66.9% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018
Q3 2016 -$7.06M -$1.17M -$167K -16.6% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 -$6.9M -$3.46M -$2.75M -393% 01 Apr 2016 30 Jun 2016 10-K 28 Sep 2017
Q1 2016 -$4.14M -$1.29M -$774K -150% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 -$3.37M -$1.14M -$894K -359% 01 Oct 2015 31 Dec 2015 10-Q 14 Feb 2017
Q3 2015 -$2.47M -$1.01M -$769K -323% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 -$1.71M -$701K -$579K -471% 01 Apr 2015 30 Jun 2015 10-K 28 Sep 2016
Q1 2015 -$1.13M -$517K -$412K -395% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 -$715K -$249K -$24K -10.6% 01 Oct 2014 31 Dec 2014 10-Q 16 Feb 2016
Q3 2014 -$691K -$238K +$70.4K +22.8% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015
Q2 2014 -$761K -$123K +$66.8K +35.2% 01 Apr 2014 30 Jun 2014 10-K 30 Sep 2015
Q1 2014 -$828K -$104K +$125K +54.5% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$953K -$225K +$221K +49.6% 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015
Q3 2013 -$1.17M -$309K +$187K +37.8% 01 Jul 2013 30 Sep 2013 10-Q 19 Nov 2014
Q2 2013 -$1.36M -$190K +$2.35M +92.5% 01 Apr 2013 30 Jun 2013 10-K 14 Oct 2014
Q1 2013 -$3.71M -$229K +$2.87M +92.6% 01 Jan 2013 31 Mar 2013 10-Q 20 May 2014
Q4 2012 -$6.58M -$447K +$2.43M +84.5% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$9.01M -$496K +$2.58M +83.9% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 -$11.6M -$2.54M 01 Apr 2012 30 Jun 2012 10-K 15 Oct 2013
Q1 2012 -$3.09M -$2.59M -509% 01 Jan 2012 31 Mar 2012 10-Q 20 May 2013
Q4 2011 -$2.88M -$2.39M -485% 01 Oct 2011 31 Dec 2011 10-Q 20 Feb 2013
Q3 2011 -$3.07M 01 Jul 2011 30 Sep 2011 10-Q 19 Nov 2012
Q1 2011 -$508K 01 Jan 2011 31 Mar 2011 10-Q 21 May 2012
Q4 2010 -$492K 01 Oct 2010 31 Dec 2010 10-Q/A 07 Mar 2012

Propanc Biopharma, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$57.3M -$55.7M -3629% 01 Jul 2024 30 Jun 2025 10-K 29 Sep 2025
2024 -$1.54M +$241K +13.5% 01 Jul 2023 30 Jun 2024 10-K 29 Sep 2025
2023 -$1.78M +$214K +10.8% 01 Jul 2022 30 Jun 2023 10-K 30 Sep 2024
2022 -$1.99M -$179K -9.86% 01 Jul 2021 30 Jun 2022 10-K 28 Sep 2023
2021 -$1.81M +$1.68M +48.1% 01 Jul 2020 30 Jun 2021 10-K 28 Sep 2022
2020 -$3.49M -$880K -33.6% 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021
2019 -$2.61M +$1.35M +34% 01 Jul 2018 30 Jun 2019 10-K 01 Oct 2020
2018 -$3.96M +$1.78M +31% 01 Jul 2017 30 Jun 2018 10-K 15 Oct 2019
2017 -$5.74M +$1.16M +16.8% 01 Jul 2016 30 Jun 2017 10-K 17 Sep 2018
2016 -$6.9M -$5.19M -304% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 -$1.71M -$944K -124% 01 Jul 2014 30 Jun 2015 10-K 28 Sep 2016
2014 -$761K +$601K +44.1% 01 Jul 2013 30 Jun 2014 10-K 30 Sep 2015
2013 -$1.36M +$10.2M +88.2% 01 Jul 2012 30 Jun 2013 10-K 14 Oct 2014
2012 -$11.6M -$9.35M -418% 01 Jul 2011 30 Jun 2012 10-K 15 Oct 2013
2011 -$2.24M 01 Jul 2010 30 Jun 2011 10-K 15 Oct 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.